March 18, 2020 10:14 AM EDTUpdated 10:57 AM

Sage plots comeback plan for its experimental oral antidepressant

Natalie Grover

Reporter

Trials testing depression drugs invariably tend to disappoint. Perhaps the most keenly-anticipated depression trial of 2019, despite great analyst and investor optimism, also failed in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage plots comeback plan for its experimental oral antidepressant

Natalie Grover

Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

Roivant brings rare disease program closer as Immunovant CEO retires

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Sage plots come­back plan for its ex­per­i­men­tal oral an­ti­de­pres­sant

Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Sage plots comeback plan for its experimental oral antidepressant